Every year, cancer claims the lives of more than half a million Americans and is the second leading cause of death in the United States https://www.cdc.gov/cancer/dcpc/data/types.htm. Novel immunotherapies against both hematological and solid malignancies have come to the forefront of treating these diseases and have demonstrated great promise.
TLR-4 & TLR-7/8 agonists are capable of reducing tumor size and slowing tumor growth in pre-clinical cancer models, especially when used in combination with other approved cancer therapies such as chemotherapy, radiation, and monoclonal antibody therapy.
Tragically, from 1999 to 2018 over 450,000 people died from an opioid overdose. Deaths among teenagers attributed to synthetic opioids such as fentanyl have tripled over the past two years alone. In response to the growing opioid epidemic, Inimmune is developing an anti-fentanyl vaccine in collaboration with the University of Montana, University of Minnesota, and Columbia University, supported by NIH funding from the HEAL (Helping to End Addition Long term) initiative.
Infections caused by multidrug-resistant (MDR) bacteria such as Pseudomonas aeruginosa (Pa) are a growing threat to human life. The World Health Organization (WHO) recently categorized Pa as a priority pathogen of the greatest risk to human health. PA opportunistically infects diabetic wounds, cystic fibrosis airways, and medical materials (such as ventilators, bandages, and catheters), resulting in hospital acquired infections.
Vaccines are one of the most successful medical interventions in human history, saving 2.5 million lives per year and protecting millions more from severe illness and hospitalization, according to the WHO. Despite this incredible success, there are many infectious diseases for which effective vaccines do not currently exist. One strategy to developing new or more protective vaccines is through the addition of adjuvants, which help activate the immune system.
TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING
Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Professional doctor or nurse giving flu or COVID-19 injection to patient. Woman in medical face mask getting antiviral vaccine at hospital or health center during vaccination and immunization campaign.